重组人血管内皮抑制素注射液持续微量泵入联合化疗治疗晚期恶性肿瘤的临床研究  

Clinical research of recombinant human endostatin injection continuous pumping combined with chemotherapy in the treatment of advanced malignant tumors

作　　者：赵文飞 魏红梅 马晓燕 孙翠萍 霍云华 王颂平 

机构地区：[1]山东省青岛市中心肿瘤医院肿瘤综合治疗二科,266000 [2]山东省青岛市中心肿瘤医院综合治疗一科,266000 [3]总装备部北京奥林佳苑干休所

出　　处：《肿瘤研究与临床》2015年第7期465-468,共4页Cancer Research and Clinic

基　　金：中国博士后科学基金面上资助项目（20090451574）;中华国际医学交流基金（CIMF-F-H001-300）

摘　　要：目的：观察重组人血管内皮抑制素注射液持续微量泵入联合化疗治疗多种晚期恶性实体肿瘤的安全性及临床疗效。方法回顾性分析156例晚期恶性实体瘤患者的临床资料，患者按治疗方式分为单纯化疗组（78例）、重组人血管内皮抑制素联合化疗组（78例）。两组在病种、分期、年龄、性别、一般状况评分及化疗方案等方面临床资料相近。治疗两个周期后据RECIST评价近期疗效和生命质量。结果联合化疗组总有效率为39.74%（31／78）；单纯化疗组总有效率为17.95%（14／78），两组差异具有统计学意义（P＜0.05）。联合化疗组中患者生活质量（QOL）改善42例（53.8%），稳定26例（33.3%），下降10例（12.8%）；单纯化疗组中患者QOL改善30例（38.5%），稳定17例（21.8%），下降31例（39.7%），两组QOL改善率差异有统计学意义（P＜0.05）；两组的主要不良反应均为骨髓抑制及消化道反应，均能耐受，两组不良反应发生率差异无统计学意义（P＞0.05）。结论重组人血管内皮抑制素持续微量泵入与化疗药物联合应用治疗晚期恶性实体肿瘤，能够有效控制和延缓病情进展，改善患者的QOL，且安全、低毒、耐受性好，值得临床进一步观察研究。Objective To investigate the safety and clinical efficacy of recombinant human endostatin injection （endostar） continuous pumping combine with chemotherapy injection in the treatment of advanced malignancies . Methods 156 patients with advanced cancer were divided into the chemotherapy group （78 cases） and the chemotherapy combined with endostar group （78 cases）. The two groups were similar in the tumor types, the neoplasm staging, the KPS and the chemotherapy agents. After two cycles chemotherapy, the efficacy was evaluated according to RECIST criteria and the quality of life （QOL） was assessed by KPS scores. Results The objective response rate （RR） of the chemotherapy combined with endostar group was 39.74%（31/78）. The RR of the chemotherapy group was 17.95%（14/78）. There was statistics significance in the RRs of the two groups （P〈0.05）. The QOL of 42 cases （53.8%） were improved, 26 cases （33.3%） were in stable and 10 cases （12.8%） were decreased in the chemotherapy combined with endostar group. The QOL were improved in 30 cases （38.5 %）, stabled in 17 cases （21.8 %） and decreased in 31 cases （39.7 %） in the chemotherapy group. There were significant difference between the two groups （P〈 0.05）. The main adverse reactions were myelosuppression and digestive tract reaction in both groups （P〉0.05）, and all patients can tolerate. Conclusion The QOL of patients with advanced malignant tumors are improved by endostar combined with chemotherapy which is safe and effective. It is worthy further clinical observation.

关 键 词：血管内皮抑制素 肿瘤 药物疗法 联合 抗肿瘤血管生成 

分 类 号：R734.2[医药卫生—肿瘤]